Holen Sie sich die Stockscreener-App
1.29
5.15%
-0.07
Schlusskurs vom Vortag:
$1.36
Offen:
$1.34
24-Stunden-Volumen:
2.32M
Relative Volume:
0.06
Marktkapitalisierung:
$67.99M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-4.23M
KGV:
-6.1195
EPS:
-0.2108
Netto-Cashflow:
-
1W Leistung:
-0.77%
1M Leistung:
-14.00%
6M Leistung:
+216.18%
1J Leistung:
+0.00%
1-Tages-Spanne:
$1.27
$1.38
1-Wochen-Bereich:
$1.14
$1.38
52-Wochen-Spanne:
$0.1135
$3.9099
Klotho Neurosciences Inc Stock (KLTO) Company Profile
Firmenname
Klotho Neurosciences Inc
Sektor
Branche
Telefon
646-916-5315
Adresse
1115 BROADWAY, NEW YORK
Vergleichen Sie KLTO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KLTO
Klotho Neurosciences Inc
|
1.29 | 47.44M | 0 | -4.23M | 0 | -0.2108 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Klotho Neurosciences Inc Aktie (KLTO) Neueste Nachrichten
Is Klotho Neurosciences Inc. a good long term investmentFree Trading Psychology Coaching - Jammu Links News
Is Klotho Neurosciences Inc. Equity Warrant a good long term investmentBreakthrough capital growth - Jammu Links News
Klotho Neurosciences Inc. Equity Warrant Stock Analysis and ForecastExceptional gains - Jammu Links News
What analysts say about Klotho Neurosciences Inc. Equity Warrant stockExplosive capital appreciation - Jammu Links News
Klotho Neurosciences Regains Nasdaq Compliance - TipRanks
What drives Klotho Neurosciences Inc. Equity Warrant stock priceExceptional market performance - Jammu Links News
Klotho Neurosciences Inc. Stock Analysis and ForecastExceptional earning trajectories - Jammu Links News
What analysts say about Klotho Neurosciences Inc. stockConsistently profitable trades - Jammu Links News
Will Klotho Neurosciences Inc. stock benefit from interest rate changesFree Stock Trading Community - Newser
Klotho Clears Nasdaq Hurdle—KLTO Stock Remains On The Big Board - Benzinga
Klotho Neurosciences regains NASDAQ compliance - Investing.com
Klotho Neurosciences Regains NASDAQ Listing Compliance. - AInvest
Biotech Firm Klotho Neurosciences Overcomes NASDAQ Delisting Risk: Full Compliance Achieved - Stock Titan
What makes Klotho Neurosciences Inc. Equity Warrant stock price move sharplyDaily Trade Opportunity - Newser
Why Klotho Neurosciences Inc. Equity Warrant stock attracts strong analyst attentionCapital Protected Stock Selections - Newser
Why Klotho Neurosciences Inc. stock attracts strong analyst attentionChart Based Entries - Newser
How Klotho Neurosciences Inc. Equity Warrant stock performs during market volatilityFree Stock Selection with 300% Return - Newser
How Klotho Neurosciences Inc. stock performs during market volatilityLow Risk Trading Ideas - Newser
What makes Klotho Neurosciences Inc. stock price move sharplyFree Real-Time Trading Opportunities - Newser
FDA Grants Orphan Status to UAB ALS Gene Therapy - Mirage News
Klotho Neurosciences Receives FDA Orphan Drug Designation - MSN
Stock Shift: KLTO’s Rollercoaster Week in The Markets - StocksToTrade
Why Did Klotho Neurosciences Plunge 14.38% Despite FDA Designation? - AInvest
Klotho Neurosciences Stock Jumps As FDA Grants Orphan Drug Tag To ALS Gene Therapy - Asianet Newsable
Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease") - The Malaysian Reserve
Why Klotho Surged 50% Overnight? - StocksToTrade
Klotho Stock Delivers 1,222% Biotech Blowout: Opportunity or Bubble? - Benzinga
Klotho Neurosciences’ ALS therapy awarded FDA Orphan Drug Designation - Proactive financial news
Klotho’s ALS candidate gains US orphan drug designation - BioWorld MedTech
Klotho Neurosciences stock soars after FDA grants orphan drug status for ALS - Investing.com Nigeria
US Stocks Likely To Open Lower A Day After Nasdaq Hits Record High: Nvidia, Kellogg, Klotho In Focus - Benzinga
Klotho Neurosciences Receives US FDA Orphan Drug Designation for Potential ALS Drug Candidate - MarketScreener
Why Did Klotho Neurosciences Stock Soar 45.99%? - AInvest
Why Did Klotho Neurosciences Soar 16.79%? - AInvest
FDA Breakthrough: New Gene Therapy Shows Promise for Lou Gehrig's Disease Treatment - Stock Titan
Klotho Neurosciences Navigates Debt Reduction and NASDAQ Compliance Amid Gene Therapy Growth Potential - AInvest
Klotho Neurosciences Surges: What’s Driving the Gains? - timothysykes.com
Why Did Klotho Neurosciences Soar 61.11%? - AInvest
Biotech Stock Rips Following Key Announcement - The Globe and Mail
Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS - Weekly Voice
Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protein in the World's Longest-Lived Population - Taiwan News
Finanzdaten der Klotho Neurosciences Inc-Aktie (KLTO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):